Massive Debut! Anthem Biosciences Share Price Jumps Over 27% on NSE and BSE What’s Next?

Anthem Biosciences IPO made a bumper listing on Dalal Street on Monday, July 21st. The stock opened at Rs. 723.10 on the BSE and Rs. 723.05 on the NSE, giving the investors a huge 26.85% listing gain over the IPO issue price of Rs. 570 per share. The IPO listing was almost in line with the expected premium in the grey market.

Anthem Biosciences Share Price Today on BSE and NSE

As of 10:30 AM, Anthem Biosciences share price on the BSE was trading at Rs. 730.70, up Rs. 7.60 or 1.05% from the listing price and a 28.19% gain over the issue price. On the NSE, the stock was quoted at Rs. 730.75 per share with a 1.06% intraday rise and a 28.20% increase from the IPO price.

Anthem Biosciences IPO Details, Subscription & GMP

The Anthem Biosciences IPO was a fully offer-for-sale (OFS) issue worth Rs. 3,395.79 crore, involving the sale of 5.96 crore equity shares. The IPO opened for subscription on July 14, 2025, and closed on July 16, 2025. The IPO allotment was finalised on July 17, 2025, and the stock got listed on both BSE and NSE on July 21. The IPO had a price band of Rs. 570 per share.

During the subscription window, the Anthem Biosciences IPO saw an overwhelming demand and was subscribed 67.42 times overall. The QIB portion was subscribed a massive 192.80 times, the retail category saw 5.98 times subscription, while the NII segment recorded 44.70 times subscription.

Because of this strong enthusiasm, the last recorded Anthem Biosciences IPO GMP was Rs. 179 as of July 21, 08:57 AM, as per Investorgain data. The expected listing gain was 31.40%. While the actual listing was slightly below this projection, the 26.85% premium is still a blockbuster listing for the Anthem Biosciences IPO.

About Anthem Biosciences Ltd.

Anthem Biosciences Limited was incorporated in 2006 and is a leading Contract Research, Development, and Manufacturing Organisation (CRDMO). The company operates across the full drug development lifecycle, offering services from discovery to commercial manufacturing.
Its offerings include fermentation-based APIs, probiotics, enzymes, peptides, vitamin analogues, and biosimilars. The company serves a global clientele of innovative biotech startups and large pharmaceutical giants, as per company data.